13D Filing: Levin Capital Strategies and Fluidigm Corp (FLDM)

Page 1 of 18

Fluidigm Corp (NASDAQ:FLDM): John A. Levin’s Levin Capital Strategies filed an amended 13D.

You can check out Levin Capital Strategies’ latest holdings and filings here.

Please follow Levin Capital Strategies (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Levin Capital Strategies or update its stock holdings.

Follow John A. Levin's Levin Capital Strategies

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Levin Capital Strategies 0 0 12,424,234 12,424,234 32.1%
Levin Capital Strategies GP 0 0 12,424,234 12,424,234 32.1%
Bi-Directional Disequilibrium Master Fund, Ltd. (f k a Levin Capital Trilogy Master Fund, Ltd.) 0 0 89,363 89,363 Less than 1%
LCS 0 0 89,363 89,363 Less than 1%
Levcap Alternative Fund 0 0 56,820 56,820 Less than 1%
LCS Event Partners 0 0 56,820 56,820 Less than 1%
Safinia Partners 0 0 19,818 19,818 Less than 1%
LCS L S 0 0 19,818 19,818 Less than 1%
John A. Levin 5,000 5,000 12,424,234 12,429,234 32.2%

Follow John A. Levin's Levin Capital Strategies

Page 1 of 18 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

(Rule 13d-101)

INFORMATION TO BE INCLUDED
IN STATEMENTS FILED PURSUANT

TO § 240.13d-1(a)
AND AMENDMENTS THERETO FILED PURSUANT TO

§ 240.13d-2(a)

(Amendment No. 3)1

Fluidigm Corporation

(Name
of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

34385P108

(CUSIP Number)

John A. Levin

Levin Capital Strategies, L.P.

595 Madison Avenue, 17th Floor

New York, NY 10022

(212) 259-0800

(Name, Address and Telephone Number of Person

Authorized to Receive Notices
and Communications)

March 2, 2018

(Date of Event Which Requires
Filing of This Statement)

If
the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule
13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following
box
¨.

Note:  Schedules
filed in paper format shall include a signed original and five copies of the schedule, including all exhibits.  See
§ 240.13d-7 for other parties to whom copies are to be sent.

1
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.

The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Follow Standard Biotools Inc. (NASDAQ:LAB)

Page 1 of 18